ASSURE: Inducing Apo A-1 agent failed to reduce atherosclerotic plaque

Induction apoA-1  synthesis is a new therapeutic approach for the functional HDL particles generation. The RVX-208 induces apoA-1  synthesis with favorable effect on HDL cholesterol. The impact of this drug on cholesterol plaque has not been investigated in humans. The objective of this study was to test the effects of RVX-208 100 mg twice a day  in the atherosclerotic disease progression assessed by coronary intravascular ultrasound (IVUS) in patients with coronary disease and low HDL. 323 patients were randomized with low HDL and simultaneously receiving treatment with atorvastatin or rosuvastatin to RVX-208 (244 patients) versus placebo (80 patients). The primary endpoint was the modification of percentage volume of atheroma regarding baseline. 

Regression was observed over plaque in the RVX-208 group but did not reach statistical significance. Liver enzymes increased significantly in the active branch (7% versus 0%, p = 0.009).

There was no difference in cardiovascular events between the two groups (13.8% in RVX-208 group versus 7.4% in the placebo group p = 0,09).

Conclusion:

There was a reduction trend in the atheroma plaque with RVX-208 that did not reach statistical significance.

S%20J%20Nicholls
S J Nicholls
2013-09-02

Original title: ASSURE: Effect of an Oral Agent Inducing Apo A-I Synthesis on Progression of Coronary Atherosclerosis: Results of the ASSURE Study

More articles by this author

PURE: Cardiovascular disease contrast between developed and undeveloped countries.

80% of the global burden of cardiovascular disease is located in countries with low or middle incomes. The aim of this study was to...

SAVOR-TIMI 53: Saxagliptin showed no cardiovascular benefit

The cardiovascular safety and efficacy of some hypoglycemic including saxagliptin (Onglyza), an inhibitor of dipeptidyl peptidase 4 (DPP-4), is not well established. 16492 patients were...

COMPARE: Losartan shows promising results in patients with Marfan syndrome

Patients with Marfan syndrome (connective tissue disorder) are more susceptible to aortic dilation and consequently dissection and sudden death. Current treatment recommends prophylactic surgery...

EXAMINE: The alogliptin is safe for treating type 2 diabetes in patients with a recent history of acute coronary syndrome.

Type 2 diabetes is associated both microvascular and macrovascular disease. Adequate glycemic control can reduce the risk of many microvascular complications but have not...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...